OncoMatch/Clinical Trials/NCT07671885
Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)
Is NCT07671885 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Adjuvant systemic therapy based on pathological findings and ET response and Adjuvant systemic therapy based on pathological findings for breast cancer.
Treatment: Adjuvant systemic therapy based on pathological findings and ET response · Adjuvant systemic therapy based on pathological findings
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
Required: ESR1 expression (≥ 10%)
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG PS 0-1
Demographics
Prior therapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07671885 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages